Tenofovir disoproxil is a prodrug that is hydrolysed to tenofovir and subsequently phosphorylated intracellularly to tenofovir diphosphate. Tenofovir diphosphate competitively inhibits HIV reverse transcriptase and HBV DNA polymerase and causes DNA-chain termination. Fumarate is the salt component; the disoproxil moiety is the prodrug.
Indications / reported uses
Treatment of HIV-1 infection in combination with other antiretroviral agents
Treatment of chronic hepatitis B in adults and adolescents where authorised; use requires current product-specific eligibility, renal assessment and monitoring
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Tenofovir Disoproxil Environmental Risk Assessment (ERA) (the Tenofovir Disoproxil ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.